Nektar Therapeutics Balance Sheet - Quarterly (NASDAQ:NKTR)

Add to My Stocks
$58.44 $1.75 (3.09%) NKTR stock closing price Sep 20, 2018 (Closing)

The financial analysis of a company like Nektar Therapeutics involves checking the three financial statements of the company in detail, of which the balance sheet is one. How cash on hand has increased or decreased is one of the many indicators used while undertaking the Nektar Therapeutics stock analysis, and provides insights into the firm's financial performance. Quarterly results announcements include the release of all three financial statements, of which the balance sheet is one. Apart from analyzing Nektar Therapeutics revenue Nektar Therapeutics operating cash flow, one needs to check balance sheet items like cash, fixed assets and debt. The Nektar Therapeutics balance sheet for 2018 Q2 shows cash on hand of $911.13M. The company has a debt to equity ratio of 0.13.

View and download Nektar Therapeutics quarterly results to get the balance sheet details for the latest 40 quarters data.
show more
View Previous Quarters
View Next Quarters
Fiscal year is Jan - Dec2018 Q22018 Q12017 Q42017 Q32017 Q22017 Q12016 Q42016 Q32016 Q22016 Q1
Marketable Securities912.68M261.85M291.37M314.6M249.39M335.04M329.46M190.21M219.17M215.77M
Raw Materials1.81M1.74M1.79M1.75M1.54M1.88M2.05M2.38M2.63M3.05M
Work In Progress9.48M7.91M4.84M8.39M7.2M9.76M7.31M6.69M6.63M7.44M
Finished Goods-1.01M4.08M3.5M2.25M1.36M1.74M1.67M1M-
Notes Receivable----------
Other Current Assets34.94M13.07M14.94M13.26M7.49M7.88M10.36M4M5.42M5.59M
Total Current Assets
Property Plant & Equipment--162.55M---176.84M---
Accumulated Depreciation--115.09M---111.24M---
Net Property Plant & Equipment
Investment & Advances282.28M37.15M57.08M59.59M45.16M3.49M----
Other Non-Current Assets----------
Deferred Charges----------
Deposits & Other Assets3.36M---1.1M-----
Total Assets
Notes Payable----------
Accounts Payable10.67M11.37M4.78M8.56M6.24M6.95M2.81M7.11M2.32M2.34M
Current Portion Long-Term Debt----------
Current Portion Capital Leases---2.48M2.7M2.9M2.9M2.37M3.61M4.78M
Accrued Expenses58.15M49.68M31.98M39.58M31.85M29.57M35.14M37.63M36.99M31.06M
Income Taxes Payable----------
Other Current Liabilities28.08M19.63M19.39M41.91M31.81M39.08M31.35M29.17M36.34M27.74M
Total Current Liabilities
Deferred Taxes/Income13.78M12.8M19.02M56.22M48.97M51.66M51.88M57.08M60.13M59.58M
Convertible Debt----------
Long-Term Debt246.08M245.64M245.2M244.77M244.33M243.9M243.46M243M242.56M242.13M
Non-Current Capital Leases----1.05M1.6M2.22M2.14M2.75M3.32M
Other Long-Term Liabilities95.92M99.35M100.64M104.35M105.48M108.04M110.95M114.4M117.61M121.16M
Total Liabilities
Minority Interest----------
Preferred Stock----------
Common Stock Net----------
Capital Surplus3.09B2.26B2.21B2.17B2.15B2.13B2.11B1.91B1.9B1.89B
Retained Earnings-1.23B-2.2B-2.12B-2.08B-2.14B-2.09B-2.02B-1.98B-1.94B-1.89B
Treasury Stock----------
Other Liabilities-4M-2.79M-2.11M-1.9M-1.66M-1.84M-2.36M-1.96M-2.01M-1.83M
Shareholders Equity1.86B58.28M87.82M84.16M3.38M44.74M88.12M-67.85M-39.25M-0.27M
Total Liabilities & Shareholders Equity2.31B496.79M508.86M582.05M475.85M528.48M568.87M425.09M463.09M491.87M
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Quarters
View Next Quarters

Most investors just check the Nektar Therapeutics stock price, and Nektar Therapeutics historical stock prices before investing. While share price is an important factor, one should also look at financials and valuation metrics like the Nektar Therapeutics PE ratio chart. Below is a brief explanation of common balance sheet terms:

  • Assets: Anything that the Nektar Therapeutics company owns and is a part of its books. Assets can be of three types: fixed, current and other assets which includes intangibles, advances. Internet companies typically don't have a lot of assets as there is not much investment in say machinery, equipment etc. Nektar Therapeutics had total assets of $2.31B.
  • Liabilities include short term loans and long term loans availed by the company to fund its business operations. NKTR stock had total liabilities of $452.67M for the quarter 2018 Q2.

Nektar Therapeutics Balance Sheet - Key Ratios

Current ratio
Debt to equity ratio
Asset turnover ratio
Receivables turnover
Price to book ratio